Earnings ·
Reports Q3 net income of $137M and on track to merge with Supernus Nov. 2
INDVSupernus, Inc.
Indivior Pharmaceuticals reported third-quarter 2026 total net revenue of $356 million, a 13% increase year-over-year, driven by record SUBLOCADE net revenue of $267 million, up 22%. GAAP net income reached $137 million ($1.12 diluted EPS), while adjusted EBITDA rose 76% to $211 million. The company confirmed it is on track to close its all-stock merger with Supernus Pharmaceuticals on November 2, 2026, after shareholders approved the transaction in October. Indivior operates as a leader in long-acting injectable treatments for opioid use disorder.